Clinical trial
Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure
NCT02627196 is registered in ClinicalTrials.gov with CVRx, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure
- Lead sponsor
- CVRx, Inc.
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- April 19, 2016
- Completion date
- October 31, 2023
- Enrollment
- 1,090 (actual)
- Sites
- 92
Conditions
As the registry lists them; a condition with its own page is linked.